- Open Access
Cerebral venous sinus thrombosis (CVST) associated with SARS-CoV-2 vaccines: clues for an immunopathogenesis common to CVST observed in COVID-19
Journal of Anesthesia, Analgesia and Critical Care volume 1, Article number: 15 (2021)
Severe acute respiratory syndrome coronavirus type 2 has been responsible for an unprecedented pandemic, and nowadays, several vaccines proved to be effective and safe, representing the only available strategy to stop the pandemic. While millions of people have safely received vaccine, rare and unusual thrombotic events have been reported and are undergoing investigations to elucidate their nature. Understanding initial trigger, underlying pathophysiology and the reasons for specific site localization of thrombotic events are a matter of debate.
We here propose that rare cases of cerebral venous sinus thrombosis, a clinical event that may rapidly evolve to brain death, reported after COVID-19 vaccine, might be consequent to an immune response resulting in inflamed/damaged endothelium, an event similar to that described for cases of cerebral venous sinus thrombosis reported during COVID-19 and not necessarily related to anti-Platelets Factor 4 antibodies, as recently described. Remarkably, in the two patients presenting at our hospital with cerebral venous sinus thrombosis and evolved to brain death, proper tissue perfusion and function maintenance allowed organ donation despite extensive thrombosis in the organ donors, with favorable outcome at 6 months.
Increased vigilance, close multidisciplinary collaboration, and further prospective research will help to better elucidate a very rare and still not fully understood pathophysiological event associated with vaccines for severe acute respiratory syndrome coronavirus 2.
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has been responsible for an unprecedented pandemic since its first description, late 2019. Less than 1 year since the first appearance of the virus on the scene, several vaccines proved to be effective and safe and received approval for emergency use. Vaccines are essential to mitigate the effects of the SARS-CoV2 virus on public health, and their importance is universally recognized as the only available strategy to stop the pandemic.
While millions of people have safely received vaccine, rare and unusual thrombotic events, termed vaccine–induced immune thrombotic thrombocytopenia (VITT), have been reported [1,2,3,4,5,6,7,8,9,10,11], with a mortality of 39–41%, mainly for hemorrhagic or ischemic brain injury [6, 12]. Thrombotic events have been mainly associated with adenoviral vector-based vaccines, but more rarely described also in association with mRNA vaccines [13,14,15].
Although VITT is an extremely rare complication, it might be fatal, especially when presenting as cerebral venous sinus thrombosis (CVST), and this has created diffuse concerns and stimulated research to elucidate underlying pathomechanisms.
In this article, we propose our viewpoint on the mechanisms underlying CVST associated with COVID-19 vaccines, a partially unknown clinical event that may rapidly evolve to brain death, and we briefly report two fatal cases of ChAdOx1 nCov-19 (Astrazeneca) vaccine-associated CVST and thrombocytopenia occurred at our institution.
VITT has been recently reported to occur 5 to 48 days, median 14, after anti-COVID-19 vaccination, with cerebral veins being the most common thrombotic site at presentation, followed by the deep veins of the legs, pulmonary arteries, and splanchnic-vein thrombosis . The baseline platelet count and the presence of intracranial hemorrhage are independent predictors of death, with an observed mortality of 73% among patients with platelet counts below 30,000 per cubic millimeter and intracranial hemorrhage .
However, CVST has also been reported as a rare neurologic complication of COVID-19 [17,18,19,20,21,22,23,24,25]. Very importantly, CVST is rare in the general population as well as after adenovirus-based SARS-CoV-2 vaccination, but appears to be several-fold more common in hospitalized patients with COVID-19, with a reported weighted average of 2.4, 3.6 and 207.1 per million, respectively . Similarly, in a large population of 537,913 COVID-19 patients, the absolute incidence of CVT was 42.8 per million patients and was significantly greater than in a matched control cohort . In a retrospective multicenter study of 13,500 consecutive patients with COVID-19 hospitalized in the USA, CVST was reported with an incidence of 8.8 per 10,000 during a 3-month study, extremely higher than the expected incidence in the general population of 5 per million annually .
CVST associated with COVID-19 should represent the result of a prothrombotic inflammatory state caused by anti-SARS-CoV2 immune response targeting vessel endothelium, which express ACE2, i.e., one of the main cellular receptors for SARS-CoV2. Indeed, endothelial injury and microvascular inflammation are recognized as a feature of COVID-19 and a major contributor to hypercoagulability observed along the disease.
Because all vaccines currently approved in our country act via the production of virus-associated proteins able to target angiotensin-converting enzyme 2 (ACE2), also the immune response occurring after vaccine could putatively generate inflammatory events targeting vascular beds, similarly to COVID-19.
Nevertheless, clinical presentation of the recently published cases of VITT has been proposed to resemble heparin-induced thrombocytopenia (HIT), a life-threatening complication of heparin treatment. HIT is caused by the production of platelet-activating IgG antibodies that recognize multimolecular complexes of (cationic) platelet factor 4 (PF4) bound to (polyanionic) heparin .
Clinical symptoms and laboratory features of this prothrombotic state have been described also in a subset of patients not having received heparin, referred as autoimmune HIT (aHIT) . Indeed, besides heparin, other polyanions, such as DNA and RNA, polyphosphates and bacterial wall can induce the conformational changes in PF4 required to expose neo-antigens .
While most of the published reports hypothesized pathologic antibodies to PF4 as the keystone of VITT, similar to autoimmune HIT, we hypothesize that rare cases of CVST reported after vaccine might be also contributed by a prothrombotic event secondary to inflamed/damaged endothelium, similarly to what described for cases of CVST reported during COVID-19 and, thus, not necessarily related to anti-PF4 antibodies. The presence of anti-PF4 antibodies, which is detectable in 90% of vaccine-induced CVST patients , might be a concomitant phenomenon secondary to immune-mediated cell damage leading to circulating DNA, another negatively charged compound that forms an immunogenic complex with the positively charged PF4. As mentioned above, nucleic acids are able to bind PF4 and change its conformation, eventually resulting in exposure of new epitopes responsible of auto-antibodies production . Interestingly, an 11-month follow-up study demonstrated that anti-PF4 antibodies are transient in most patients with VITT and become negative in 66% of the patients . Furthermore, the kinetics of anti-PF4 antibodies in VITT compared to HIT is currently unknown and requires further studies . Molecular mimicry between spike protein and PF4 epitopes has also been proposed . More importantly, following immunization with COVID-19 vaccine, CVST can occur in the absence of anti-PF4 antibodies .
Considering the timing of CVST occurrence upon vaccine administration, a role for vaccine-induced, anti-spike immune response appears likely. We envisage, as a hypothesis for VITT pathogenesis, that the vaccine could lead to an adaptive immune response able to eventually target and damage cells that express the receptors for the spike-associated proteins induced by the vaccine, including endothelial cells. In this instance, a main pathogenic role would be played by the presence of not yet identified individual predisposing factors, which call for further research to better elucidate the mechanism and guide future directions.
The reasons why this immunogenic thrombosis preferentially occurs in cerebral venous vessels are still unclear, but a different density or polymorphism of specific immunoglobulin receptors (CD32) in endothelial cells might play a role . Others suggest a strong expression of Coxsackie-adenovirus-receptors and adhesion molecules on central nervous system .
The endothelium contributes to the local balance between pro- and anti-inflammatory mediators as well as procoagulant and anticoagulant activities. Furthermore, in different vascular beds, endothelial cells exhibit properties that are specific of the local environment. This could further explain the different susceptibility of CVST as preferential site of VITT phenomena. Immunohistochemical findings of post-mortem examinations suggest endothelial activation sustaining procoagulant conditions and thrombus formation .
Given the physiological circulatory route of cerebrospinal fluid, thrombosis might occur due to the spread of vaccine-associated inflammatory mediators or effector cells to the vascular endothelium of the sinus venous or to direct extension into the sinus venous of the immunocomplexes present into the cerebrospinal fluid. Interestingly, SARS-CoV2 infection preceded the symptoms of CVST by up to two weeks, as reported in recent cases of VITT, which, again, represent the interval of time necessary for obtaining an effective adaptive immune response.
In Table 1 and Fig. 1, we present two fatal cases of ChAdOx1 nCov-19 (Astrazeneca) vaccine-associated CVST and thrombocytopenia, both complicated by cerebral hemorrhage rapidly evolving to brain death, that were admitted to our university hospital in March 2021. Worthwhile to signal, and in agreement with an immune-based pathogenesis associated with an endothelial injury, a high ScvO2 value occurred in case 2, which might therefore suggest an inability of the cells to extract oxygen or a micro-circulatory shunting due to endothelium damage.
Antibodies to platelet factor 4 (PF4) were positive in both patients, as previously described in some other reported cases of VITT . Consistent with an assumed autoimmune mechanism, treatments for these VITT were anticoagulants different from heparin (fondaparinux), high dose intravenous immunoglobulins and steroids [36, 37]. Despite treatment, deterioration of neurological picture occurred, with refractory intracranial hypertension leading to brain death. Following patient will and thanks to organ perfusion/function maintenance, despite severe acute thrombotic events, successful organ donation was possible in both cases, with 6 months good outcomes in recipients.
As VITT is a potentially fatal event associated with vaccine against a much more devastating pandemic, it is imperative that science move forward illuminated by wisdom and prudence. High index of suspicion and prompt diagnosis are extremely important to ensure immediate hospitalization and therapy [36, 37], since CVST associated with either vaccines or COVID-19 seems to evolve much more rapidly and with a higher level of fatalities than CVST with different etiology .
Finally, if brain death occurs, careful organ donor management, including mitigating inflammatory response, can allow functional organs to be successfully transplanted to save other lives.
Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
Vaccine–induced immune thrombotic thrombocytopenia
Severe acute respiratory syndrome coronavirus 2
Cerebral venous sinus thrombosis
Coronavirus disease 2019
Platelet factor 4
Superior sagittal sinus
Angiotensin-converting enzyme 2
Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt A-H, Skattør TH, Tjønnfjord GE, Holme PA (2021) Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 384(22):2124–2130. https://doi.org/10.1056/NEJMoa2104882
von Hundelshausen P, Lorenz R, Siess W, Weber C (2021) Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with bruton tyrosine kinase inhibitors. Thromb Haemost. 121(11):1395–1399. https://doi.org/10.1055/a-1481-3039
Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, Ay C, Korte W, Scharf RE, Pötzsch B, Greinacher A (2021) Erratum: Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie. 41(3):e1. https://doi.org/10.1055/s-0041-1729135
Cines DB, Bussel JB (2021) SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med N Engl J Med. 384(23):2254–2256. https://doi.org/10.1056/NEJMe2106315
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S (2021) Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med N Engl J Med. 384(22):2092–2101. https://doi.org/10.1056/NEJMoa2104840
Dotan A, Shoenfeld Y (2021) Perspectives on vaccine induced thrombotic thrombocytopenia. J Autoimmun. 121:102663. https://doi.org/10.1016/j.jaut.2021.102663
See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, Streiff MB, Rao AK, Wheeler AP, Beavers SF, Durbin AP, Edwards K, Miller E, Harrington TA, Mba-Jonas A, Nair N, Nguyen DT, Talaat KR, Urrutia VC, Walker SC, Creech CB, Clark TA, DeStefano F, Broder KR (2021) US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA 325(24):2448–2456. https://doi.org/10.1001/jama.2021.7517
Muir K-L, Kallam A, Koepsell SA, Gundabolu K (2021) Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 384(20):1964–1965. https://doi.org/10.1056/NEJMc2105869
Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, Goldblatt D, Kotoucek P, Thomas W, Lester W (2021) Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med 384(23):2202–2211. https://doi.org/10.1056/NEJMoa2105385
Perry RJ, Tamborska A, SinghB, Craven B, Marigold R, Arthur-Farraj P, Yeo JM, Zhang L, Hassan-Smith G, Jones M, Hutchcroft C, Hobson E, Warcel D, White D, Ferdinand P, Webb A, Solomon T, Scully M, Werring DJ, Roffe C, CVT after immunisation against COVID-19 (CAIAC) collaborators (2021) Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study. Lancet S0140-6736(21)01608-01601. doi: https://doi.org/10.1016/S0140-6736(21)01608-1.
Thakur KT, Tamborska A, Wood GK, McNeill E, Roh D, Akpan IJ, Miller EC, Bautista A, Claassen J, Kim CY, Guekht A, Pardo CA, Williams O, García-Azorín D, Prasad K, Schmutzhard E, Michael BD, Chou SHY, Winkler AS, Solomon T, Elkind MS (2021) Clinical review of cerebral venous thrombosis in the context of COVID-19 vaccinations: evaluation, management, and scientific questions. J Neurol Sci 427:117532. https://doi.org/10.1016/j.jns.2021.117532
Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A (2021) Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review. Neurol Sci 428:117607. https://doi.org/10.1016/j.jns.2021.117607
Carli G, Nichele I, Ruggeri M, Barra S, Tosetto A (2021) Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Intern Emerg Med. 16(3):803–804. https://doi.org/10.1007/s11739-021-02685-0
Dias L, Soares-Dos-Reis R, Meira J, Ferrão D, Soares PR, Pastor A, Gama G, Fonseca L, Fagundes V, Carvalho M (2021) Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine. J Stroke Cerebrovasc Dis. 30(8):105906. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.105906
Smadja DM, Yue QY, Chocron R, Sanchez O, Lillo-Le Louet A (2021) Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase. Eur Respir J. 2100956(1). https://doi.org/10.1183/13993003.00956-2021
Pavord S, Scully M, Hunt BJ, Lester W, Bagot C, Craven B, Rampotas A, Ambler G, Makris M (2021) Clinical features of vaccine-induced immune thrombocytopenia and thrombosis. N Engl J Med doi 385(18):1680–1689. https://doi.org/10.1056/NEJMoa2109908
Nwajei F, Anand P, Abdalkader M, Arasa VCA, Aparicio HJ, Behbahani S, Curiale G, Daneshmand A, Dasenbrock H, Mayo T, Mian A, Nguyen T, Ong C, Romero JR, Sakai O, Takahashi C, Cervantes-Arslanian AM (2020) Cerebral venous sinus thromboses in patients with SARS-CoV-2 infection: three cases and a review of the literature. J Stroke Cerebrovasc Dis 29(12):105412. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105412
Hughes C, Nichols T, Pike M, Subbe C, Elghenzai S (2020) Cerebral venous sinus thrombosis as a presentation of COVID-19. Eur J Case Rep Intern Med 7:001691
Hemasian H, Ansari B (2020) First case of COVID-19 presented with cerebral venous thrombosis: a rare and dreaded case. Rev. Neurol. (Paris) 176(6):521–523. https://doi.org/10.1016/j.neurol.2020.04.013
Klein DE, Libman R, Kirsch C, Arora R (2020) Cerebral venous thrombosis: a typical presentation of COVID-19 in the young. J Stroke Cerebrovasc Dis 29(8):104989. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104989
Dakay K, Cooper J, Bloomfield J, Overby P, Mayer SA, Nuoman R, Sahni R, Gulko E, Kaur G, Santarelli J, Gandhi CD, Al-Mufti F (2021) Cerebral venous sinus thrombosis in COVID-19 infection: a case series and review of the literature. J Stroke Cerebrovasc Dis 30(1):105434. https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105434
Cavalcanti DD, Raz E, Shapiro M, Dehkharghani S, Yaghi S, Lillemoe K, Nossek E, Torres J, Jain R, Riina HA, Radmanesh A, Nelson PK (2020) Cerebral venous thrombosis associated with COVID-19. AJNR Am J Neuroradiol 41(8):1370–1376. https://doi.org/10.3174/ajnr.A6644
Bikdeli B, Chatterjee S, Arora S, Monreal M, Jimenez D, Krumholz HM, Goldhaber SZ, Elkind MSV, Piazza G (2021) Cerebral venous sinus thrombosis in the U.S. population, after adenovirus-based SARS-CoV-2 vaccination, and after COVID-19. J Am Coll Cardiol 78(4):408–411. https://doi.org/10.1016/j.jacc.2021.06.001
Taquet M, Husain M, Geddes JR, Luciano S, Harrison PJ (2021) Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases. EClinicalMedicine 39:101061. https://doi.org/10.1016/j.eclinm.2021.101061
Al-Mufti F, Amuluru K, Sahni R, Bekelis K, Karimi R, Ogulnick J, Cooper J, Overby P, Nuoman R, Tiwari A, Berekashvili K, Dangayach N, Liang J, Gupta G, Khandelwal P, Dominguez JF, Sursal T, Kamal H, Dakay K, Taylor B, Gulko E, El-Ghanem M, Mayer SA, Gandhi C (2021) Cerebral venous thrombosis in COVID-19: a New York Metropolitan cohort study. Am J Neuroradiol 42(7):1196–1200. https://doi.org/10.3174/ajnr.A7134
Greinacher A, Selleng K, Warkentin TE (2017) Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 15(11):2099–2114. https://doi.org/10.1111/jth.13813
Chong BH, Chong JJ-H (2013) HIT: nucleic acid masquerading as heparin. Blood 122(2):156–158. https://doi.org/10.1182/blood-2013-05-504126
Schönborn L, Thiele T, Kaderali L, Greinacher A (2021) Decline in pathogenic antibodies over time in VITT. N Engl J Med 2112760(19):1815–1816. https://doi.org/10.1056/NEJMc2112760
Othman M, Baker AT, Gupalo E, Elsebaie A, Bliss CM, Rondina MT, Lillicrap D, Parker AL (2021) To clot or not to clot? Ad is the question—insights on mechanisms related to vaccine-induced thrombotic Thrombocytopenia. J Thromb Haemost.19:2845–2856.
McGonagle D, De Marco G, Bridgewood C (2021) Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. Journal of Autoimmunity 121:102662. https://doi.org/10.1016/j.jaut.2021.102662
Dutta A, Ghosh R, Bhattacharya D, Bhat S, Ray A, Pandit A, Das S, Dubey S (2021) Anti-PF4 antibody negative cerebral venous sinus thrombosis without thrombocytopenia following immunization with COVID-19 vaccine in an elderly non-comorbid Indian male, managed with conventional heparin-warfarin based anticoagulation. Case Reports Diabetes Metab Syndr. 15(4):102184. https://doi.org/10.1016/j.dsx.2021.06.021
Amiral J, Vissac AM (2019) Update on mechanisms, pathogenicity, heterogeneity of presentation, and laboratory diagnosis of heparin-induced thrombocytopenia. DOI. https://doi.org/10.5772/intechopen.86475
De Cristofaro R, Sanguinetti M (2021) Vaccine-induced thrombotic thrombocytopenia, a rare but severe case of friendly fire in the battle against COVID-19 pandemic: what pathogenesis? Eur J Intern Med 91:88–89. https://doi.org/10.1016/j.ejim.2021.06.020
Pomara C, Sessa F, Ciaccio M, Dieli F, Esposito M, Garozzo SF, Giarratano A, Prati D, Rappa F, Salerno M, Tripodo C, Zamboni P, Mannucci PM (2021) Post-mortem findings in vaccine-induced thrombotic thombocytopenia. Haematologica 106(8):2291–2293. https://doi.org/10.3324/haematol.2021.279075
Marchandot B, Carmona A, Trimaille A, Curtiaud A, Morel O (2021) Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis. J Thromb Thrombolysis. 1-3. 52(3):689–691. https://doi.org/10.1007/s11239-021-02505-4
Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, Ay C, Korte W, Scharf RE, Pötzsch B, Greinacher A (2021) Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie 41(3):184–189. https://doi.org/10.1055/a-1469-7481
Furie KL, Cushman M, MSV E, Lyden PD, Saposnik G, American Heart Association/American Stroke Association Stroke Council Leadership (2021) diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia. Stroke 52(7):2478–2482. https://doi.org/10.1161/STROKEAHA.121.035564
Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F, for the ISCVT Investigators (2004) Prognosis of cerebral vein and dural sinus thrombosis. Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 35(3):664–670. https://doi.org/10.1161/01.STR.0000117571.76197.26
No funding was received for the preparation of this article.
Ethics approval and consent to participate
The Ethic Committee of the Hospital has been notified, as per local protocol, of the submission of the cases inside the manuscript for publication.
Consent for publication
GF has received fees as a lecturer and consultant, as well as research grants from the following organizations: Lallemand Pharma, BG-Clinicals, Biogen, Beckman Coulter, Becton-Dickinson, PharmNDev. AA was appointed as technical consultant for the CEO for Italy of the AZD1222 vaccine manufacturer (Astra Zeneca) in a legal proceeding initiated by the Public Prosecutor’s Office at the Court of Syracuse. AN has received fees for educational events on hemodynamic monitoring form Edwards Lifescience. ATM, FG, KG, RM, CDG, FP, MCF, AG, and CM have no disclosures.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mazzeo, A.T., Noto, A., Asmundo, A. et al. Cerebral venous sinus thrombosis (CVST) associated with SARS-CoV-2 vaccines: clues for an immunopathogenesis common to CVST observed in COVID-19. J Anesth Analg Crit Care 1, 15 (2021). https://doi.org/10.1186/s44158-021-00020-9
- Cerebral venous sinus thrombosis
- Brain death
- Organ donation